Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Nissan Chem. claims hypoglycemic agents for diabetes

Oct. 11, 1996

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Appetite-suppressing effects of urocortin

Oct. 11, 1996

Pravastatin continues to demonstrate clinical utility in various patient groups

Oct. 11, 1996

Generic cholestyramine cleared by FDA

Oct. 11, 1996

New hypocholesterolemic agent from Schering-Plough

Oct. 11, 1996

Second Hedgehog-based research collaboration for Ontogeny

Oct. 11, 1996

New introduction for fertility hormone

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.